Elite Health 2025 10-K: $1.024M Revenue, $(0.35) EPS

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Elite Health reported $1.024 million in revenue for the year ended December 31, 2025, primarily from PSS employee-leasing services following a November 2025 acquisition, and recorded a loss per share of $(0.35) as net loss widened. The company posted an operating loss and a net loss for the year as it invested in launching Medicare Advantage operations and absorbed acquisition-related items. These results reflect the early contribution of the acquired business and investments to support the company's strategic pivot.

Financial Highlights

  • Revenue: $1.024 million, recorded from PSS employee-leasing revenue for two months after the November 2025 acquisition.
  • Gross Profit: $0.118 million, reported as Revenue less Cost of revenue.
  • Operating Income: $(3.839) million, reported as operating loss (selling, general and administrative expense of $3.957 million).
  • Net Income: $(7.804) million, reported as net loss for the year ended December 31, 2025.
  • Net Income Per Share: $(0.35), basic and diluted net loss per share attributable to Elite Health.

Business Highlights

  • Acquisition and Immediate Contribution: Acquired PSS in November 2025, which added goodwill and accounts receivable and generated immediate service revenue from employee-leasing operations.
  • Strategic Pivot: Executing a shift to build and operate Medicare Advantage plans, with initial focus on California.
  • Operational Investments: Capitalized expenditures on software and website development to support the launch of Medicare Advantage operations.
  • Going Concern and Funding: Raised private placement proceeds in 2025 to fund the Medicare Advantage launch and support operations into 2026.

Original SEC Filing: Elite Health Systems Inc. [ EHSI ] - 10-K - Apr. 15, 2026

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.